stockrowRegeneron Pharmaceuticals, Inc. (REGN) vs Roivant Sciences Ltd. (ROIV)
- Regeneron Pharmaceuticals, Inc. REGN 908.99 +0.67%
- Roivant Sciences Ltd. ROIV 38.81 +5.98%
Regeneron Pharmaceuticals, Inc. and Roivant Sciences Ltd. are both Biotechnology companies. Regeneron Pharmaceuticals, Inc. is the larger, with a market value of $93.4B against $26.5B — 3.5× the size. Roivant Sciences Ltd. has negative trailing earnings, so its P/E is not meaningful; Regeneron Pharmaceuticals, Inc. trades at 19.2×. Regeneron Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 18.6% against −67.6%. Regeneron Pharmaceuticals, Inc. has the higher net margin (28.5% vs −3,535.0%) and the higher return on invested capital (11.6% vs −34.5%). Across the 19 metrics below, Regeneron Pharmaceuticals, Inc. leads on 17 and Roivant Sciences Ltd. on 2.
Valuation
Profitability
| Metric | REGN | ROIV | Biotechnology median |
|---|---|---|---|
| Gross margin | 85.77% | 81.21% | 65.16% |
| Operating margin | 28.79% | (7,914.75%) | 0.00% |
| Net margin | 28.51% | (3,534.96%) | 0.00% |
| Free cash flow margin | 21.47% | (10,901.00%) | 0.00% |
| Return on equity | 14.95% | (5.47%) | (50.12%) |
| Return on assets | 11.39% | (5.15%) | (45.60%) |
| Return on invested capital | 11.61% | (34.51%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack